{
  "meta": {
    "id": "test35",
    "title": "Drugs_Affecting_Blood_and_Blood_formation-Anti_Platelets_and_Pro_Platelets__Thrombolytics_and_Anti_Thrombolytics",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A 70-year-old woman came with complaints of sudden onset of pain, swelling, and redness in her left calf. She has been experiencing difficulty walking and standing for the past two days. She has a history of hypertension and high cholesterol, which is being managed with diet and medication. On giving which of the following drugs will we need to monitor her clotting time for?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Heparin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Alteplase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Apixaban",
          "correct": false
        }
      ],
      "correct_answer": "B. Heparin",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/UurFmSyBXU8bYvCEfnmH1724134747.jpg"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "ba41599e"
    },
    {
      "text": "A 58-year-old female patient with a history of atrial fibrillation visits for routine follow-up. She has been prescribed an antiplatelet drug to reduce her risk of stroke. Her medication regimen includes clopidogrel, which she has been taking for the past six months without any adverse effects. Which receptor is primarily targeted by clopidogrel to inhibit platelet aggregation?",
      "options": [
        {
          "label": "A",
          "text": "P2Y12 receptor",
          "correct": true
        },
        {
          "label": "B",
          "text": "GP IIb/IIIa receptor",
          "correct": false
        },
        {
          "label": "C",
          "text": "COX-1 enzyme",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombin receptor",
          "correct": false
        }
      ],
      "correct_answer": "A. P2Y12 receptor",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/bavUtsN4bL6Ip91rJg7y1724134811.jpg",
        "https://image.prepladder.com/content/rgeRMbiKRxTf6gIZGjK11724134847.jpg"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "11a34e50"
    },
    {
      "text": "A 65-year-old male presents with acute chest pain suggestive of MI. He has a history of hypertension, hyperlipidemia, and type 2 diabetes mellitus. Which of the following is the most appropriate initial dose of aspirin for this patient?",
      "options": [
        {
          "label": "A",
          "text": "75 mg orally",
          "correct": false
        },
        {
          "label": "B",
          "text": "150 mg orally",
          "correct": false
        },
        {
          "label": "C",
          "text": "325 mg orally",
          "correct": true
        },
        {
          "label": "D",
          "text": "500 mg orally",
          "correct": false
        }
      ],
      "correct_answer": "C. 325 mg orally",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "30ffe0cd"
    },
    {
      "text": "A 72-year-old female patient with a history of atrial fibrillation and coronary artery disease is scheduled for elective hip replacement surgery in two weeks. She has been taking low-dose aspirin (75 mg daily) for secondary prevention of MI and stroke. Which of the following is the most appropriate management regarding her aspirin therapy before surgery?",
      "options": [
        {
          "label": "A",
          "text": "Continue aspirin at the same dose through the surgery.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Stop aspirin immediately and resume after the surgery.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stop aspirin 7-10 days before surgery and resume after the surgery.",
          "correct": true
        },
        {
          "label": "D",
          "text": "Switch from aspirin to clopidogrel until after the surgery.",
          "correct": false
        }
      ],
      "correct_answer": "C. Stop aspirin 7-10 days before surgery and resume after the surgery.",
      "question_images": [],
      "explanation_images": [
        "https://image.prepladder.com/content/GiT9ngXjjZX7g8wYIWm11724134968.jpg"
      ],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "6efff208"
    },
    {
      "text": "A 65-year-old male with a history of hypertension and type 2 diabetes presents with chest pain and is diagnosed with acute coronary syndrome. The cardiology team decides to initiate antiplatelet therapy. Which of the following ADP receptor blockers would be the best choice if the team wants an agent with reversible action?",
      "options": [
        {
          "label": "A",
          "text": "Vorapaxar",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prasugrel",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ticagrelor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Ticlopidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ticagrelor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Irreversible blockers (prodrugs)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Reversible blockers (active drugs)</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Ticlodipine.<strong>(Option D)</strong></li>\n<li>Clopidogrel</li>\n<li>Prasugrel.<strong>(Option B)</strong></li>\n</ul>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Ticagrelor.</li>\n<li>Cangrelor: IV drug (used during <span class=\"customMeta\" data-dictid=\"b2fb1a3a5416927771953ea4fa15e1\">percutaneous</span> <span class=\"customMeta\" data-dictid=\"7c48bba0a71692777200073b077d94\">transluminal</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> angiography- PTCA).</li>\n</ul>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "d82d3efd"
    },
    {
      "text": "A 58-year-old man presents with a sudden onset of severe chest pain radiating to his left arm. He is diaphoretic and appears anxious. His medical history includes hypertension and hyperlipidemia. An ECG shows ST-segment elevation in the anterior leads, and laboratory tests reveal elevated troponin levels. The cardiologist considers initiating therapy with prasugrel. Which of the following conditions is a contraindication for the use of prasugrel in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Hypertension",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hyperlipidemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "History of ischemic stroke",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diabetes mellitus",
          "correct": false
        }
      ],
      "correct_answer": "C. History of ischemic stroke",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "2f27de72"
    },
    {
      "text": "A 60-year-old male with a history of stable angina is currently on a regimen that includes aspirin and nitrates. His cardiologist decides to add a new medication to his treatment plan to prevent thrombotic events further. After a few weeks, the patient reports increased episodes of chest pain, particularly during physical exertion. The cardiologist suspects that it might be coronary steal syndrome. Which of the following medications is most likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Pentoxifylline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dipyridamole",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cilostazol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Aspirin",
          "correct": false
        }
      ],
      "correct_answer": "B. Dipyridamole",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Common uses</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Notes</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Pentoxifylline</p>\n<p><strong>(Option A)</strong></p>\n</td>\n<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\"><br/>\n<br/>\n<br/>\n<br/>\n\t\t\t\u00a0\n\t\t\t<p>Used as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in cases of Stroke and Buerger's disease</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>\u00a0Improves blood <span class=\"customMeta\" data-dictid=\"337d16dac5169277718474b97f6e4a\">circulation</span> (rheological agent)</li>\n<li>\u00a0Increases <span class=\"customMeta\" data-dictid=\"d6c754309d16927771874142ec8ca4\">elasticity</span> of RBCs</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Cilostazol</p>\n<p><strong>(Option C)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">-</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Dipyridamole</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>\u00a0Dipyridamole is approved for secondary prevention of stroke when it is combined with aspirin</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "bf400a69"
    },
    {
      "text": "A 55-year-old male with a history of myocardial infarction is being evaluated for ongoing chest pain and shortness of breath. The patient's current medication regimen includes aspirin, a beta-blocker, and a statin. The cardiologist considers adding a Phosphodiesterase 3 (PDE-3) inhibitor to further manage the patient's symptoms but recalls that certain PDE-3 inhibitors are contraindicated in patients with myocardial infarction. Which is the correct reason for PDE-3 inhibitors being contraindicated in patients with a history of myocardial infarction?",
      "options": [
        {
          "label": "A",
          "text": "They increase the risk of bleeding.",
          "correct": false
        },
        {
          "label": "B",
          "text": "They cause severe hypotension.",
          "correct": false
        },
        {
          "label": "C",
          "text": "They may inhibit PDE3 in the heart, leading to increased cardiac stimulation and oxygen demand.",
          "correct": true
        },
        {
          "label": "D",
          "text": "They can cause bradycardia and heart block.",
          "correct": false
        }
      ],
      "correct_answer": "C. They may inhibit PDE3 in the heart, leading to increased cardiac stimulation and oxygen demand.",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "3bf5dd56"
    },
    {
      "text": "A 65-year-old male patient with a history of chronic kidney disease presents to the emergency department with severe chest pain. An electrocardiogram (ECG) confirms an acute myocardial infarction (MI). The cardiologist decides to proceed with percutaneous coronary intervention (PCI) and considers using a glycoprotein IIb/IIIa inhibitor to prevent further thrombotic events during the procedure. Given the patient's renal condition, which glycoprotein IIb/IIIa inhibitor is most appropriate for this patient?",
      "options": [
        {
          "label": "A",
          "text": "Eptifibatide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Abciximab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Tirofiban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Aspirin",
          "correct": false
        }
      ],
      "correct_answer": "B. Abciximab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td colspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">GpIIb/IIIa inhibitors</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Drug</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Structure</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Common Uses</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Route</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Abciximab</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Monoclonal antibody</p>\n</td>\n<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Acute attack of MI</p>\n<p style=\"text-align:center\">\u00a0</p>\n<p style=\"text-align:center\">Stroke</p>\n<p style=\"text-align:center\">\u00a0</p>\n<p style=\"text-align:center\">Stent replacement <strong>(Percutaneous <span class=\"customMeta\" data-dictid=\"7c48bba0a71692777200073b077d94\">transluminal</span> <span class=\"customMeta\" data-dictid=\"bc8bc758371692777185eff2ccabb7\">coronary</span> angioplasty)</strong></p>\n</td>\n<td rowspan=\"3\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><br/>\n\t\t\t\u00a0</p>\n<p style=\"text-align:center\">i.v.</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Eptifibatide</p>\n<p style=\"text-align:center\"><strong>(Option A)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Peptide molecule</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Tirofiban</p>\n<p style=\"text-align:center\"><strong>(Option C)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Non-peptide molecule</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "1e90b61e"
    },
    {
      "text": "Which of the following statements about newer antiplatelet drugs is incorrect?",
      "options": [
        {
          "label": "A",
          "text": "Vorapaxar is a PAR (Protease Activating Receptor) inhibitor.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Blocking PAR receptors on platelets prevents the attachment of thrombin, leading to no platelet aggregation.",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dazoxiben is a thromboxane A2 synthase inhibitor.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dazoxiben is recently approved as an add-on drug to aspirin in myocardial infarction (MI).",
          "correct": true
        }
      ],
      "correct_answer": "D. Dazoxiben is recently approved as an add-on drug to aspirin in myocardial infarction (MI).",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:613px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Drug Name</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Drug Type</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Mechanism of Action</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Approval Status</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Vorapaxar</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">PAR (Protease Activating Receptor) inhibitor</p>\n<p style=\"text-align:center\"><strong>(Option A)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Blocks <span class=\"customMeta\" data-dictid=\"bb9e0041f71692777194e60188e1b6\">PAR</span> <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> on platelets, preventing <span class=\"customMeta\" data-dictid=\"ac7e1f394f1692777200c5bb11e4d8\">thrombin</span> <span class=\"customMeta\" data-dictid=\"ccd357daaf16927771825777ea6a0d\">attachment</span> and <span class=\"customMeta\" data-dictid=\"e7032bae7f1692777195d693722e54\">platelet</span> aggregation</p>\n<p style=\"text-align:center\"><strong>(Option B)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Recently approved as an add-on drug to <span class=\"customMeta\" data-dictid=\"deba671f4716927771828c95a320e5\">aspirin</span> in MI</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Dazoxiben</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Thromboxane A2 <span class=\"customMeta\" data-dictid=\"d2bd91ccac169277719941254e1795\">synthase</span> inhibitor</p>\n<p style=\"text-align:center\"><strong>(Option C)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Arachidonic Acid (via COX-1 enzyme)</p>\n<p style=\"text-align:center\">\u2193</p>\n<p style=\"text-align:center\">Prostaglandin G2 (via <span class=\"customMeta\" data-dictid=\"96309dcb1c169277720072ad555473\">Thromboxane</span> A2 Synthase)</p>\n<p style=\"text-align:center\">\u2193</p>\n<p style=\"text-align:center\">Thromboxane A2 (TxA2)</p>\n<p style=\"text-align:center\">Dazoxiben blocks <strong>Thromboxane A2 Synthase</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Under trial for MI</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "54a55045"
    },
    {
      "text": "A 45-year-old female presents to the clinic with a history of easy bruising, petechiae, and prolonged bleeding from minor cuts. Laboratory tests reveal a significantly low platelet count, and she is diagnosed with idiopathic thrombocytopenic purpura (ITP). The physician decides to start treatment to increase her platelet count. Which of the following pro-platelet drugs is most appropriate for treating this patient's condition?",
      "options": [
        {
          "label": "A",
          "text": "Vorapaxar",
          "correct": false
        },
        {
          "label": "B",
          "text": "Oprelvekin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Romiplostim",
          "correct": true
        },
        {
          "label": "D",
          "text": "Abciximab",
          "correct": false
        }
      ],
      "correct_answer": "C. Romiplostim",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td colspan=\"4\" style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Pro-Platelet Drugs</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Drug Name</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Drug Type</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Route</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\"><strong>Uses</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Romiplostim</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Recombinant <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of thrombopoietin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Subcutaneous injection</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Treatment of <span class=\"customMeta\" data-dictid=\"4acddc3cf5169277718996440e2e14\">idiopathic</span> thrombocytopenic <span class=\"customMeta\" data-dictid=\"0acd34c758169277719644923511e5\">purpura</span> (ITP)</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Eltrombopag</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Thrombopoietin <span class=\"customMeta\" data-dictid=\"9e4959f6f316927771978bb152d440\">receptor</span> agonist</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Oral</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Treatment of <span class=\"customMeta\" data-dictid=\"57ddcfb8ec1692777190b76f23c2e5\">ITP</span> and chronic liver disease</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Oprelvekin</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Recombinant <span class=\"customMeta\" data-dictid=\"a1b06f401f1692777203a53393ba98\">form</span> of IL-11</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">Subcutaneous injection</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p style=\"text-align:center\">DOC in chemotherapy-induced thrombocytopenia</p>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "https://image.prepladder.com/content/UaYbEHuq5O63XxfbY7f41747297647.mp3",
      "video": "",
      "uid": "ad7e2514"
    },
    {
      "text": "Which of the following drugs is approved for immune thrombocytopenia (ITP) ?",
      "options": [
        {
          "label": "A",
          "text": "Fostamatinib",
          "correct": true
        },
        {
          "label": "B",
          "text": "Bosutinib",
          "correct": false
        },
        {
          "label": "C",
          "text": "Oprelvekin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Erlotinib",
          "correct": false
        }
      ],
      "correct_answer": "A. Fostamatinib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<table cellspacing=\"0\" style=\"border-collapse:collapse; width:624px\">\n<tbody>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Drug </strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Class</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p><strong>Use</strong></p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Fostamatinib</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>BTK inhibitor</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Chronic immune thrombocytopenia</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Bosutinib</p>\n<p><strong>(Option B)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Tyrosine <span class=\"customMeta\" data-dictid=\"9863da498e1692777190e1c6515b48\">kinase</span> inhibitor</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Chronic, accelerated, or blast-phase Ph+ <span class=\"customMeta\" data-dictid=\"32c39405871692777184d06d6c01ab\">CML</span> with resistance or <span class=\"customMeta\" data-dictid=\"7794e5fd7a1692777190ee626ede62\">intolerance</span> to prior therapy</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Oprelvekin</p>\n<p><strong>(Option C)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Thrombopoietic growth factor (recombinant IL-11)</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Patients undergoing <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> for non-myeloid malignancies with severe thrombocytopenia</p>\n</td>\n</tr>\n<tr>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>Erlotinib</p>\n<p><strong>(Option D)</strong></p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<p>EGFR inhibitor</p>\n</td>\n<td style=\"border-bottom:1px solid #000000; border-left:1px solid #000000; border-right:1px solid #000000; border-top:1px solid #000000; vertical-align:top\">\n<ul>\n<li>Patients with advanced or metastatic Non-Small Cell Lung Cancer after failure of platinum-based <span class=\"customMeta\" data-dictid=\"8602c4b260169277718439bb122cb0\">chemotherapy</span> treatment</li>\n</ul>\n<ul>\n<li>Newly diagnosed Non-Small Cell Lung Cancer patients with EGFR mutations</li>\n<li>In combination with gemcitabine for the treatment of patients with locally advanced, unresectable, or metastatic pancreatic cancer</li>\n</ul>\n</td>\n</tr>\n</tbody>\n\n\n<p style='font-size: 10px; color: #808080; font-style: italic;'></p>",
      "bot": "@dams_new_robot",
      "audio": "",
      "video": "",
      "uid": "b6b25eb4"
    }
  ]
}